Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Blocking vascular endothelial growth factor pathway can enhance the efficacy of EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study conducted in the People’s Republic of China evaluating apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inh...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of thoracic oncology 2021-09, Vol.16 (9), p.1533-1546
Hauptverfasser:	Zhao, Hongyun, Yao, Wenxiu, Min, Xuhong, Gu, Kangsheng, Yu, Guohua, Zhang, Zhonghan, Cui, Jiuwei, Miao, Liyun, Zhang, Li, Yuan, Xia, Fang, Yong, Fu, Xiuhua, Hu, Chengping, Zhu, Xiaoli, Fan, Yun, Yu, Qitao, Wu, Gang, Jiang, Ou, Du, Xiuping, Liu, Jiwei, Gu, Wei, Hou, Zhiguo, Wang, Quanren, Zheng, Rongrong, Zhou, Xianfeng
Format:	Artikel
Sprache:	eng
Schlagworte:	Apatinib Epidermal growth factor receptor Non–small cell lung cancer Targeted therapy Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!